20170406 Telix Logo.png
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
07 mars 2022 17h37 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...